Pregnancy is strongly discouraged in patients with pulmonary arterial hypertension (PAH). Herein, we report a successful delivery in a woman with PAH using a multidisciplinary approach. A 30-year-old pregnant woman with PAH was referred to us with a chief complaint of dyspnea. She was advised to terminate her pregnancy but she refused to do so despite several recommendations by healthcare professionals. She was scheduled for treatment with iloprost (brand name: Ilomedin) and heparin infusions for 3-4 days at 20-day intervals. She spent her last month of pregnancy in a hospital under close observation and received iloprost infusion. She underwent a successful cesarean section under general anesthesia at week 36 of gestation. Iloprost administration was continued for one week after delivery and was changed to bosentan after that. Meanwhile, heparin infusion was substituted by warfarin. However, treatment with bosentan led to a temporary interruption in breastfeeding. A few days later, she presented with severe dyspnea and pulmonary artery pressure of 110 mmHg. Treatment was restarted with iloprost, followed by stabilization with bosentan. A successful delivery was achieved in this situation by meticulous observation and aggressive treatment targeting PAH, along with long-term hospital stay and multidisciplinary management. Severe PAH is regarded as a contraindication to pregnancy. While physicians strongly recommend termination of pregnancy in such patients, some of them might refuse and insist on delivery of the baby. Similar pregnant cases with potential delivery are recommended to be evaluated for effective management of this condition.
INTRODUCTION
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular (RV) failure and premature death (1) . Pulmonary complication is an ominous prognostic sign, mainly observed in patients with collagen vascular diseases (2) .
However, PAH affects a relatively small number of pregnant women (approximately 0.0003%) (1) . Epoprostenol (synthetic prostacyclin) improves exercise capacity and pulmonary hemodynamics as well as symptoms in both clinical conditions. Moreover, this substance is the only treatment associated with improved survival in PAH in a randomized study (10) . Therefore, we used iloprost for several weeks prior to the expected date of delivery in order to maximize its benefits. Iloprost therapy was continued after the delivery considering the increased incidence of postpartum complications.
Recent guidelines of the European Society of
Bosentan is the first orally active dual endothelin-A and Intravenous epoprostenol is reported to be safe during pregnancy. In this case, iloprost caused no fetal deformities or growth retardation.
The use of a "treat-to-target" strategy with frequent visits during pregnancy is recommended for these patients.
In addition, patients must be admitted during the third trimester and a multidisciplinary approach should be used to facilitate management and achieve safe delivery.
Detailed plans must be designed (e.g., timing and mode of delivery) and should be accompanied by extensive patient dialogue along with their consent as well as communication with local healthcare professionals prior to delivery (12) .
The optimal mode of delivery (cesarean section versus vaginal delivery) in patients with PAH remains a matter of debate. Urgent delivery (e.g., caesarean section) might be needed in cases of maternal hemodynamic deterioration or fetal distress. Close surveillance of fetus and a lower threshold for intervention with early signs of maternal or fetal distress were the main reasons for selecting cesarean section for our patient.
An important component in successful management of these patients involves a multidisciplinary approach with a meticulous observation of patients during pregnancy.
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